Matthew Benjamin, The Motley Fool Thu, November 12, 2026 at 12:35 PM EST 4 min read LLY +0.68% NVDA -4.67% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
The good news keeps rolling in for Eli Lilly (NYSE:LLY), sending its shares higher at the start of the trading week.
Last week, Lilly announced that phase 3 clinical trials on its experimental GLP-1 drug retatrutide showed it is effective in reducing pain from knee osteoarthritis (OA). The trials conducted at Northwestern University showed that people taking high doses of the drug lost, on average, up to 25% of their body weight and experienced a 50% reduction in OA pain.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
The two results are linked, of course, as people dealing with obesity put additional stress on their knees. The GLP-1 drug also seems to have significant anti-inflammatory effects, which is positive for the knee joint.
The trial results suggest that retatrutide could be approved by the Food and Drug Administration (FDA) for both weight loss and relief from OA pain.
In addition, Lilly and Hims & Hers Health (NYSE:HIMS) announced an agreement to expand access to two other Lilly-manufactured GLP-1s, Zepbound and Foundayo, on the Hims & Hers platform.
Finally, on Monday, Lilly announced that a phase 3 program found that its Foundayo drug significantly reduced the severity of obstructive sleep apnea. The company said the drug, which is already approved for weight loss, reduced breathing interruptions during sleep by up to 44% on average. Lilly plans to submit Foundayo to the FDA for the treatment of obstructive sleep apnea by the end of this year.
Despite the 51% run-up in Lilly's share price over the past 52 weeks, and the fact that the stock is expensive at 47 times trailing earnings, I remain extremely bullish on Lilly, as I wrote just last week.
That's because sales are exploding. Revenue rose 39% in the third quarter to $24.4 billion, and earnings per share increased 16% to $7.22. Even better, management raised its guidance for full-year revenue from between $85 billion and $87 billion to a range of $91 billion to $92 billion.
And I continue to believe that, due to the life-altering nature of GLP-1 drugs, that's just the beginning. Not only are there huge untapped markets for obesity drugs around the world, but research continues to discover new use cases. The National Institutes of Health (NIH) say the medicines improve outcomes in people with cardiovascular, kidney, liver, arthritis, and sleep apnea disorders. Those improvements are mediated in part through anti-inflammatory and metabolic pathways.
Even more astounding possibilities exist. The drugs may have the potential to treat different types of addictions and even slow the aging process, though a lot more research will be needed before they can be prescribed for those uses.
Perhaps as a result of all that news, Jefferies raised its price target for the stock from $1,610 to $1,700. It currently trades around $1,400.
If you believe, as I do, that GLP-1 drugs will cause a tectonic shift in healthcare, then you should consider investing in Lilly, as, at the moment, it's got the most momentum in this rapidly expanding market.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $348,060!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,067,492!*
Now, it's worth noting Stock Advisor's total average return is 849% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of November 12, 2026.
Matthew Benjamin has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly, Hims & Hers Health, and Jefferies Financial Group. The Motley Fool has a disclosure policy.
More Good News for Eli Lilly Sends the Stock Even Higher was originally published by The Motley Fool
